UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL				
MB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	.)													
1. Name and Address of Reporting Person Fust Matthew K (Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900 (Street)			2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA] 3. Date of Earliest Transaction (Month/Day/Year) 08/15/2016 4. If Amendment, Date Original Filed(Month/Day/Year)							Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director					
														ow)	
														Line)	
(City)		(State)	(Zip)		т	-bl-T N	D	· C							
		` ′	2. Transaction	2A. Deeme		3. Trans							neficially Ow		7. Nature
1.Title of Security (Instr. 3)			Date (Month/Day/Year)	Execution Date, any	Date, if	Code (Instr. 8)	(A	or Disp	ecurities Acquired or Disposed of (D) r. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Follo Reported Transaction(s)		Fo	Ownership form:	f Indirect Beneficial
				(Month/Da	y/Year				A) or	Ì	nstr. 3 and	4)	(r Indirect	Ownership (Instr. 4)
Common S	Stock		08/15/2016			Code		nount 6	(D)	Price \$ 0 (1)	5,491		I	(Instr. 4)	
Reminder: R	Report on a se	eparate line for ea	ch class of securiti	es beneficial	ly owr	ed directly	Persons contain	who re	s fo	rm are no	ot require	on of infor ed to resp control nu	ond unless		474 (9-02)
Reminder: R	Report on a so	eparate line for ea		es beneficial			Persons contain form dis	who re ed in th splays a	s fo	rm are no rently va	ot require	d to resp	ond unless		1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction	Table II - I (3A. Deemed Execution Date	Derivative S e.g., puts, c: 4. , if Transac Code	ecuritialls, was 5. stion of D Sc A (4 D of (I	es Acquirrants, o Number erivative eccurities ecquired () or isposed (D) nstr. 3, 4,	Persons contain form dis	s who reed in the splays a sed of, or exertible ercisable tion Dat	Ben secu	rm are no rently va reficially (ot require alid OMB of Owned	ed to resp control nu 8. Price of	ond unless	T 10. Ownersl Form of Derivati Security Direct (I or Indire	11. Natur of Indire Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II - 1 (3A. Deemed Execution Date rr)	Derivative S e.g., puts, c: 4. , if Transac Code	ecuritialls, was 5. stion of D Sc A (4 D of (I	es Acquirrants, o Number erivative excurities equired of (D) nstr. 3, 4, d 5)	Persons contain form dis red, Dispo ptions, cor 6. Date Ex and Expira	s who red in the splays a seed of, on evertible ercisable tition Datay/Year)	Ben secu	rm are no rently va reficially (rities) 7. Title an Amount o Underlyin Securities	ot require alid OMB of Owned	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported Transaction(To. Ownersl Form of Derivati Security Direct (I or Indirect) (I)	11. Natur of Indire Beneficia Ownersh (Instr. 4)

Keporung Owners

B. C. N. /All	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Fust Matthew K C/O ATARA BIOTHERAPEUTICS, INC.	37					
611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Matthew K. Fust	08/16/2016	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares issued upon settlement of vested restricted stock units.
- (2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.

The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that

(3) vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that

25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date.

(4) The earlier of (i) March 27, 2021 or (ii) the recipient's termination date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.